Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study

Melphalan 140 mg/m 2 or 200 mg/m 2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

(2017) Holger W. Auner et al.   HAEMATOLOGICA

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients

(2017) Monika Engelhardt et al.   HAEMATOLOGICA

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

(2017) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melphalan 140 mg/m 2 or 200 mg/m 2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

(2017) Holger W. Auner et al.   HAEMATOLOGICA

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients

(2017) Monika Engelhardt et al.   HAEMATOLOGICA

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study

(2016) Laurent Garderet et al.   HAEMATOLOGICA

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study

(2016) Laurent Garderet et al.   HAEMATOLOGICA

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

(2015) A. Palumbo et al.   BLOOD

High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma

(2015) T M Wildes et al.   BONE MARROW TRANSPLANTATION

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma

(2015) Holger W. Auner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

(2014) Shuji Ozaki et al.   ACTA HAEMATOLOGICA

Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation

(2014) Manish Sharma et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years

(2014) H W Auner et al.   BONE MARROW TRANSPLANTATION

Multiple Myeloma in the Older Adult: Better Prospects, More Challenges

(2014) Tanya M. Wildes et al.   JOURNAL OF CLINICAL ONCOLOGY

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

(2014) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents

(2013) M. Merz et al.   ANNALS OF ONCOLOGY

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

(2011) M. Cavo et al.   BLOOD

Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score

(2011) M Kleber et al.   Blood Cancer Journal

Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

(2009) A. Palumbo et al.   BLOOD